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ABSTRACT: Available treatments for Chagas’ disease and visceral
leishmaniasis are inadequate, and there is a pressing need for new
therapeutics. Drug discovery efforts for both diseases principally rely
upon phenotypic screening. However, the optimization of phenotypi-
cally active compounds is hindered by a lack of information regarding
their molecular target(s). To combat this issue we initiate target
deconvolution studies at an early stage. Here, we describe
comprehensive genetic and biochemical studies to determine the targets of three unrelated phenotypically active compounds. All
three structurally diverse compounds target the Qi active-site of cytochrome b, part of the cytochrome bc1 complex of the electron
transport chain. Our studies go on to identify the Qi site as a promiscuous drug target in Leishmania donovani and Trypanosoma cruzi
with a propensity to rapidly mutate. Strategies to rapidly identify compounds acting via this mechanism are discussed to ensure that
drug discovery portfolios are not overwhelmed with inhibitors of a single target.
KEYWORDS: cytochrome b, Trypanosoma cruzi, Leishmania donovani, drug target, mechanism of action
Neglected tropical diseases (NTDs) are prevalentinfectious diseases afflicting the world’s poorest people,
often living in extreme poverty earning less than $2 per day.
Consequently, it is hardly surprising that the economic drivers
for the development of novel diagnostics, drugs, vaccines, and
other interventions are sadly lacking. Among the “most
neglected” NTDs are Chagas’ disease (CD) infecting 7−8
million in Central and South America and visceral
leishmaniasis (VL), with up to 100 000 new cases arising
each year predominantly in rural India, Sudan, South Sudan,
Kenya, Somalia, Ethiopia, and Brazil. Combined, these diseases
are responsible for more than 40 000 fatalities annually and the
loss of over 1.2 million disease adjusted life years.1,2 The
accompanying economic burden of these vector-borne diseases
provides a major obstacle to improving human health.3
Current treatments for both VL and CD suffer from a range
of issues including severe toxic side effects4,5 and acquired drug
resistance.6 To compound these difficulties, many of these
chemotherapeutics also require prolonged treatment regimens7
and are prohibitively expensive. Thus, there remains a definite
and urgent need to develop low-cost, safe, effective, oral, and
short-course drugs to strengthen the range of treatment
options. Unfortunately, there are currently no new therapeutics
in advanced clinical development for either disease and
relatively few in preclinical development.8
Drug discovery efforts for CD (caused by infection with the
protozoan parasite Trypanosoma cruzi) and VL (caused by
Leishmania donovani or Leishmania infantum) are hampered by
a dearth of well-validated molecular drug targets. This has
severely curtailed target-focused drug discovery against these
parasites, leaving drug discovery programs reliant upon whole
cell (phenotypic) screening to identify effective start points.9
This approach has proven somewhat effective. However, the
downstream development and optimization of phenotypically
active compounds is often hindered by a lack of information
regarding their mechanism(s) of action and/or molecular
target(s). Specifically, issues related to compound toxicity and
poor pharmacokinetic properties can be considerably more
difficult to overcome without knowledge of the target and the
molecular context in which the compound is binding. As a
consequence, compounds identified via phenotypic screening
can suffer from disproportionately high attrition rates.10
One strategy to combat the high failure rates associated with
the development of phenotypically active compounds is to
initiate target deconvolution studies at a relatively early stage.
The association of active compounds with defined molecular
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targets during the development process can be extremely
powerful. Toxic liabilities associated with the target can be
assessed, and in cases where the target is structure-enabled,
more selective and potent versions of compound series can be
evolved. A more complete understanding of the compound
mechanism of action (MoA) can also prevent enrichment of
drug candidates against the same molecular target or the
development of inhibitors with an unattractive or invalidated
target, such as sterol 14α-demethylase (CYP51) in T. cruzi.11,12
Furthermore, this knowledge can inform future drug
combination strategies, and may lead to the identification of
novel drug targets that can be exploited by de novo target-based
drug discovery.
Here, we describe our comprehensive genetic and
biochemical studies to determine the MoA of 3 unrelated
compounds that demonstrated promising in vitro activity
against L. donovani and T. cruzi. Despite the structural diversity
of these compounds, identified as a result of independent high-
throughput screening initiatives, all 3 specifically target the Qi
active site of cytochrome b, part of the cytochrome bc1
complex of the electron transport chain (ETC). Our studies
identify the Qi site of cytochrome b as a promiscuous drug
target in L. donovani and T. cruzi. Strategies to rapidly identify
compounds acting via this MoA to prevent drug discovery
portfolios from becoming overwhelmed with cytochrome b
inhibitors are discussed.
■ RESULTS
Pyrazolopyrimidinone Compound Demonstrating
Promising Activity against L. donovani and T. cruzi.
High-throughput screening of GSK’s 1.8 M diverse compound
library against L. donovani, T. cruzi, and Trypanosoma brucei
resulted in the identification of a significant number of
compounds active against these parasites.13 Among these hits,
TCMDC-143087 was moderately active against T. cruzi
intracellular amastigotes with an EC50 value of 250 nM.
Using TCMDC-143087 as a start point, a hit-to-lead drug
discovery program was initiated and resulted in the develop-
ment of a compound series exemplified by DDD01542111
(compound 1, Figure 1). Compound 1 demonstrated
promising potency against both the mammalian (intracellular
amastigote) and insect (promastigote) stages of L. donovani
with EC50 values of 1500 ± 400 and 19 ± 1 nM, respectively
(Table 1). In addition, compound 1 was active against both
developmental stages of T. cruzi (EC50 values of 210 ± 7 and
20 ± 3 nM for epimastigotes and intracellular amastigotes,
respectively). For T. brucei, this pyrazolopyrimidinone
compound was also extremely potent against the procyclic
stage of the parasite (EC50 = 97 ± 3 nM); however, there was a
pronounced drop in activity of more than 3 orders of
magnitude against the bloodstream form (EC50 = 6600 ±
470 nM) (Table 1).
Resistance Generation and Whole Genome Sequenc-
ing. To investigate the MoA of compound 1, populations of L.
donovani and T. cruzi parasites resistant to this pyrazolopyr-
imidinone were selected. Clonal lines of drug-susceptible L.
donovani promastigotes and T. cruzi epimastigotes were
cultured in vitro in the continuous presence of compound 1
until significant levels of drug resistance emerged. L. donovani
promastigotes were exposed for a total of 140 days until they
were capable of growing in 2 μM compound 1 (equivalent to
100× the established EC50 value, Table 1). Resistance emerged
more quickly in our T. cruzi cultures with epimastigotes
exposed to drug for just 70 days capable of growing in 10 μM
compound 1 (equivalent to >80× the established EC50 value,
Table 1). Following drug selection, resistant parasites were
cloned by limiting dilution; the susceptibility of each cloned
cell line to compound 1 was determined and compared to that
of wild-type parasites (Figure 2). All cloned cell lines
demonstrated considerable levels of resistance to compound
1 with L. donovani clones between 38- and 62-fold and T. cruzi
between 12- and 32-fold less sensitive than wild-type parental
cell lines (Figure 2). In each case the resistance demonstrated
by these clones was stable over 20 passages in culture in the
absence of drug.
Whole genome sequencing of all 6 L. donovani and T. cruzi
clones resistant to compound 1 revealed mutations within the
gene encoding Cytochrome b, part of the cytochrome bc1
complex (complex III) of the ETC (Figure 3A,B). All 3 T.
cruzi clones analyzed shared the same L197F mutation in
cytochrome b (Figure 3B). Interestingly, this specific mutation
has previously been identified in T. cruzi epimastigotes that are
resistant to GNF7686 (Figure 1), an established cytochrome b
inhibitor.14 Compound 1-resistant L. donovani promastigotes
maintained two separate mutations within cytochrome b,
G37A in clones 1 and 2 and C222F in clone 3. Cytochrome b
contains 2 discrete reaction sites involved in the Q cycle: a
ubiquinone reduction center (Qi site) and a ubiquinol
oxidation center (Qo site) (Figure 3C). All of the mutations
identified in our compound 1-resistant parasites map to the Qi
center of cytochrome b (Figure 3C).
Our sequencing analysis, at a genome coverage of between
46- and 88-fold, indicates that in all cases these mutations are
homozygous. It should be noted that no other consistent single
nucleotide polymorphisms (SNPs) or copy number variations
(CNVs) that could indicate an alternative mechanism of action
and/or resistance were identified in these resistant clones
(Tables S1 and S2 and Figure S2). In the kinetoplastids,
Cytochrome b is encoded solely by kinetoplast DNA and
specifically by maxi-circle DNA.15 Mitochondrial networks can
maintain up to 50 copies of maxi-circle DNA meaning that a
single network encodes up to 50 copies of Cytochrome b. With
this in mind, we hypothesize that these mutations are likely to
Figure 1. Chemical structures.
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have arisen from a point mutation on a single copy of maxi-
circle DNA before spreading to all copies during the process of
compound selection. Collectively, these data identify cyto-
chrome b as the putative target of compound 1 in both L.
donovani and T. cruzi.
Compound 1 Inhibits Complex III Activity and
Respiration. Located in the mitochondrial inner membrane,
complex III of the ETC is composed of cytochrome b
associated with a Rieske iron−sulfur protein and cytochrome c.
Complex III accepts ubiquinol from complex II of the ETC;
the Qo and Qi sites of cytochrome b then act in tandem to
reduce cytochrome c by quinone-based electron bifurcation,
sequentially oxidizing two ubiquinol molecules to ubiquinone,
and then reducing one ubiquinone to ubiquinol.16 Since
Cytochrome b is encoded by kinetoplast DNA there is currently
no technical way of editing these genes (∼50 copies) to
validate the role of resistance-associated mutations, either by
CRISPR-cas9 or by other more traditional methods of gene
editing. In addition, episomal expression of Cytochrome b
would be unlikely to confer resistance as the overexpressed
protein would be localized to the cytoplasm rather than in the
mitochondrion where it is functionally required. Thus, to
establish if compound 1 specifically inhibits complex III
activity in L. donovani and T. cruzi, clarified cell lysates of both
parasites that were enriched for mitochondria were prepared.
Using decylubiquinol as a pseudosubstrate, the activity of
complex III in the presence and absence of test compounds
was determined by monitoring the reduction of cytochrome c
at 550 nm. In the first instance, the assay was validated using
established inhibitors of the Qi site of cytochrome b, antimycin
A17 and GNF768614 (Figure 1). As expected, both compounds
were potent inhibitors of complex III activity in lysates of L.
donovani and T. cruzi (Table 2, Figure S3). Antimycin A
demonstrated relatively equal potency against complex III from
both parasites with IC50 values of 25 ± 2 and 14 ± 3 nM in L.
donovani and T. cruzi lysates, respectively. In keeping with its
development as a small molecule inhibitor of T. cruzi,
GNF7686 was a more potent inhibitor of complex III derived
from T. cruzi epimastigotes than L. donovani promastigotes
(IC50 values of 550 ± 97 nM versus 1610 ± 300 nM,
respectively). Compound 1 also proved to be a potent
inhibitor of complex III activity in both parasite lysates,
returning IC50 values of 44 ± 7 and 72 ± 16 nM for L.
donovani and T. cruzi, respectively. Importantly, these IC50
values correlate well with the established EC50 values for
compound 1 against promastigote and epimastigote growth in
vitro (Table 1) supporting our initial hypothesis that
cytochrome b is the principal target of this pyrazolopyrimidi-
none compound. In further support of this hypothesis,
complex III activity derived from a compound 1-resistant L.
donovani clone demonstrated marked resistance to inhibition
by compound 1 compared to the equivalent activity in lysates
of WT parasites (Table S3).
During aerobic metabolism, the ETC mediates the transport
of electrons, from electron donors such as NADH or FADH2,
to the terminal electron acceptor, molecular oxygen. Thus,
inhibition of cytochrome b should result in a measurable
decrease in the consumption of O2 by parasites. To further
confirm a role in inhibition of ETC function, the rate of O2
consumption of T. cruzi epimastigotes was determined using
Table 1. Compound Efficacy: Potencies of Compounds Were Determined against L. donovani Promastigotes (Pro), L.
donovani Intramacrophage Amastigotes (Intra-MAC), T. cruzi Epimastigotes (Epi), T. cruzi Intra-Vero Cells (Intra-Vero), T.
brucei Bloodstream Forms (BSF), T. brucei Procyclics (Pro), and HepG2 Cellsa
EC50 values, nM
T. cruzi L. donovani T. brucei
compound ID Epi Intra-Vero Pro Intra-MAC BSF Pro HepG2
DDD01542111 (compound 1) 210 ± 7 20 ± 3 19 ± 1 1500 ± 400 6700 ± 470 97 ± 3 >50 000
DDD01716002 (compound 2) 71 ± 2 30 ± 10 24 ± 2 1100 ± 600 8000 ± 970 140 ± 14 >50 000
DDD00808408 (compound 3) 320 ± 12 150 ± 46 1640 ± 54 >50 000 8700 ± 470 88 ± 2 7300 ± 60
GNF7686 710 ± 17 150 ± 30b 570 ± 51 >50 000 >50 000 520 ± 13 >50 000
antimycin A 28 ± 1 NDc 2 ± 0.1 ND >50 000 18 ± 0.5 <1000
aAll data are the mean ± standard deviation of at least two biological replicates (n ≥ 2) with each biological replicate composed of three technical
replicates. In all cases, Hill slope values ranged between 1.0 and 6. bReported previously.14 cND: not determined.
Figure 2. Compound 1 resistance in vitro. Schematic representation
of the generation of compound 1-resistant cell lines in Leishmania
donovani (A) and Trypanosoma cruzi (B). Each passage of cells in
culture (circles) is indicated with clones I, II, and III indicated in
black, white, and gray, respectively. (C, D) EC50 values for compound
1 were determined for WT (closed circles) and RES I, II, and III-
resistant cell lines (black, white, and gray squares, respectively). The
curves are the nonlinear fits of data using a two-parameter EC50
equation provided by GraFit. EC50 values of 21.5 ± 0.5 and 120 ± 6
nM were determined for compound 1 against WT L. donovani and T.
cruzi, respectively. EC50 values for L. donovani RES I, II, and III were
1300 ± 14, 1300 ± 96, and 790 ± 27 nM. For T. cruzi, RES I, II, and
III returned values of 1400 ± 78, 2500 ± 62, and 3800 ± 160 nM,
respectively. EC50 values are the weighted mean ± standard deviation
of at least two biological replicates (n ≥ 2) with each biological
replicate composed of three technical replicates.
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the MitoXpress Xtra reagent in the presence of varying
concentrations of compound 1 (Table 2). Antimycin A was
once again utilized as a positive control in these assays and
returned an IC50 value of 200 ± 36 nM. Compound 1 was a
similarly potent inhibitor of T. cruzi respiration with an IC50
value of 150 ± 36 nM.
Multiple Cytochrome b Inhibitors Identified through
High-Throughput Screening. At the same time the MoA of
compound 1 was established, two unrelated compounds
demonstrating potent antikinetoplastid activity were identified
as a result of various high-throughput screening initiatives.
Compound 2 was developed from an original hit identified
from screening of an in-house 15 659 compound diversity
library against L. donovani (Figure 1). Following optimization,
this thienopyridine compound maintained its activity against L.
donovani and also proved to be a low nM inhibitor of T. cruzi
(epimastigotes and intracellular amastigotes, Table 1).
Compound 3 originated from a hit identified from screening
of a Medivir library of compounds. An iterative process of
optimization then led to the development of compound 3
(Figure 1). While compound 3 demonstrated promising
activity against T. cruzi (EC50 values of 320 ± 12 and 150 ±
46 nM for epimastigotes and intracellular amastigotes,
respectively), it was largely inactive against both developmental
stages of L. donovani. Interestingly, both compounds
demonstrated the same pronounced drop-off in activity against
bloodstream form compared to procyclic T. brucei as seen with
compound 1. This pattern of compound potency is particularly
striking since procyclics are considered the more robust form
of T. brucei and are generally more resilient to drug treatment.
In the case of compound 1, this pattern of potency is entirely
consistent with our hypothesis that compound 1 is a
cytochrome b inhibitor. Procyclic parasites are dependent
upon a classical ETC, including cytochrome b, for ATP
production; while bloodstream forms rely almost entirely on
glycolysis and do not express cytochrome b.18 Indeed, the same
differential activity against procyclic and bloodstream T. brucei
was observed with the established cytochrome b inhibitors
GNF7686 (EC50 values of 521 versus >50 000 nM) and
Figure 3. Mutations in cytochrome b confer resistance to compounds 1−3. The tables illustrate the collated mutations within L. donovani (A) and
T. cruzi (B) cytochrome b identified by WGS of clones resistant to compounds 1−3. (C) Secondary structure model of the L. donovani cytochrome
b based on the Saccharomyces cerevisiae enzyme.60 Amino acids in cytochrome b that were mutated in cell lines resistant to compounds 1−3 are
indicated by light blue circles (L. donovani only), dark blue circles (T. cruzi only), and light blue/dark blue circles (found in both parasites). Please
note that the numbering of amino acids in this model is representative of L. donovani cytochrome b. Please note that the numbering of amino acids
in T. cruzi cytochrome b is equivalent to L. donovani residues −1.
Table 2. Assessment of Compounds in Assays Measuring
Complex III Activity and Respirationa
complex III, IC50 values, nM
O2 consumption,
IC50 values, nM
compound ID L. donovani T. cruzi T. cruzi
DDD01542111
(compound 1)
44 ± 7 72 ± 16 150 ± 36
DDD01716002
(compound 2)
99 ± 13 100 ± 24 510 ± 119
DDD00808408
(compound 3)
13 000 ± 4800 86 ± 39 190 ± 38
GNF7686 1600 ± 300 550 ± 97 210b
antimycin A 25 ± 2 14 ± 3 200 ± 36
aInhibition of complex III (cytochrome c reduction) activity was
determined in lysates enriched with mitochondria isolated from L.
donovani promastigotes and T. cruzi epimastigotes. For all complex III
assays, Hill slope values ranged from 0.6 to 1.3 with the majority of
values close to 1.0. Therefore, we do not believe that these Hill slope
values are indicative of cooperativity. The respiration of T. cruzi
epimastigotes (3 × 106) at a range of compound concentrations was
determined using MitoXpress-Xtra probe (see Materials and Methods
for details). All complex III assay data are the weighted mean ±
standard deviation of at least two biological replicates (n ≥ 2) with
each biological replicate composed of three technical replicates. O2
consumption data are the weighted mean ± standard deviation of two
biological replicates (n = 2). Representative data from both assays are
shown in Figure S3. bReported previously.14
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Figure 4. Cross-resistance relationships. Resistant clones bearing specific cytochrome b mutations were assessed for their response to GNF7686
(light gray), compound 1 (white), compound 2 (dark gray), and compound 3 (black). EC50 values were determined and compared to the EC50
values established with these compounds against wild-type parasites. (A) Data generated with L. donovani-resistant promastigotes. (B) Data
generated with T. cruzi epimastigotes. All data are the mean ± standard deviation of at least two biological replicates (n ≥ 2) with each biological
replicate composed of three technical replicates. (C, D) Data from a single biological replicate.
Figure 5. Docking and druggability of the Qi active sites of L. donovani and T. cruzi cytochrome b. (A) Sequence alignments of the Qi site of
cytochrome b from L. donovani, T. cruzi, human, and Gallus gallus, generated using Jalview version.61 (B) Binding mode of antimycin A (green),
compound 1 (pink), compound 2 (violet), and compound 3 (cyan) in the Qi active site of cytochrome b (light-yellow cartoon). The structures
shown correspond to the L. donovani cytochrome b homology model except for the compound 3 complex where the T. cruzi model is displayed.
Residues establishing the more relevant interaction with the ligands are displayed as sticks. Haem (bH) is shown in red at the back of the cavity.
Please note that the numbering of amino acids in T. cruzi cytochrome b are equivalent to L. donovani residues −1. (C) Physicochemical properties
of the cytochrome b Qi active site. Hydrophobic (yellow), hydrogen-bond donor (blue), and hydrogen-bond acceptor (red) maps of the Qi active
site are annotated. Antimycin A (green sticks) is docked into the Qi site of cytochrome b.
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antimycin A (EC50 values of 18 versus >50 000 nM) (Table 1).
Collectively, these observations reinforce cytochrome b as the
likely molecular target of compound 1 and raise the possibility
that compounds 2 and 3 may also specifically target this key
enzyme of the ETC.
L. donovani and/or T. cruzi cell lines resistant to compounds
2 and 3 were generated in vitro, as described above (Figure
S1). Whole genome and in-house Sanger sequencing revealed
several homozygous point mutations within the Cytochrome b
genes of these resistant clones (summarized in Figure 3A−C;
see also Figure S2 and Table S4). Both compounds were
confirmed as potent inhibitors of complex III activity in
parasite cell lysates (Table 2 and Figure S3). Compound 2
inhibited complex III isolated from L. donovani and T. cruzi
parasites (IC50 values of 99 ± 13 and 100 ± 24 nM,
respectively), while compound 3 inhibited complex III from T.
cruzi epimastigotes (IC50 value of 86 ± 39 nM) but showed
little significant inhibition of complex III from L. donovani
promastigotes (IC50 > 13 000 nM). As expected, both
compounds also inhibited the respiration (O2 consumption)
of wild-type T. cruzi epimastigotes with IC50 values of 510 ±
120 and 190 ± 38 nM for compounds 2 and 3, respectively
(Table 2). This confirms that these apparently structurally
unrelated compounds (2 and 3), derived from independent
high-throughput screens, target the same molecular target as
compound 1.
Complex Cross-Resistance Relationships. We next
determined the relative sensitivity of each resistant line to
compounds 1−3 and GNF7686 (Figure 4). This analysis
revealed a complex pattern of susceptibility that appears to be
entirely driven by the specific cytochrome b mutations
represented in the respective clones. In L. donovani (Figure
4A), our resistant clones generated through selection with
compound 1 maintained either a G37A or C222F mutation.
Promastigotes bearing the G37A mutation demonstrated
hypersensitivity to compound 2, relative to wild-type parasites,
while remaining sensitive to GNF7686. In contrast, parasites
with the C222F mutation were markedly cross-resistant to
GNF7686 and hypersensitive to compound 2. Three separate
point mutations (G31A, C207P, and F227I) were identified in
the three L. donovani-resistant clones generated with
compound 2. These individual cell lines responded very
differently to treatment with compound 1 and GNF7686,
ranging from hypersensitivity to decreased susceptibility
depending on the mutations encoded in cytochrome b.
Importantly, these observations were replicated when the L.
donovani-resistant lines were assessed against compounds 1
and 2 as intracellular amastigotes within macrophages (Table
S5). Our T. cruzi-resistant clones also exhibited stark,
mutation-driven variability in their response to these various
cytochrome b inhibitors (Figure 4B).
Molecular Modeling. In order to rationalize the role of
specific mutations in decreased susceptibility and/or hyper-
sensitivity to compounds 1−3, homology models of the L.
donovani and T. cruzi cytochrome b were generated using the
crystallographic structure of the avian (Gallus gallus)
homologue as a template.19 The Qi active sites of L. donovani
and T. cruzi cytochrome exhibit 38% and 45% sequence
identity compared to the avian sequence, respectively (Figure
5A). Each model was built with ubiquinone bound in the
active site. Ramachandran plots indicated the robustness of the
L. donovani and T. cruzi models with 89% and 87% of the
residues in the most favored orientations, respectively.
Modeling results obtained from docking calculations and
refined using molecular dynamic (MD) simulations predict
that compounds 1−3 share a similar mode of binding in the Qi
active site (Figure 5B). Indeed, all 3 ligands exploit the same
hydrophobic pocket as the well-established Qi site inhibitor
antimycin A (Figure 5B,C, Figures S4 and S5). With regard to
our model with compound 1, the planar pyrazolo-pyrimidi-
none moiety binds between haem (bH) and Phe223. The
carbonyl group and the pyrazole N form two water-bridged
hydrogen bonds with the conserved D231 while hydrophobic
interactions are established between the bicycle ring and
residues L20, L201, and F223. In addition, the chloro-phenyl
ring extends toward G37, establishing hydrophobic contacts
with L198 and a stacking interaction with F34. This predicted
mode of binding goes some way to explaining the molecular
role of the G37A mutation identified in L. donovani clones
resistant to compound 1. The methyl group of the alanine side-
chain could cause a steric clash with the chloro-phenyl moiety
resulting in a drop in potency. Similarly, the L197F mutation
identified in compound 1-resistant T. cruzi would likely hinder
the binding of the ligand due to a possible steric clash with the
phenyl ring.
In our model of compound 2 (Figure 1), the planar
thienopyridine bicycle also binds close to the haem (bH), with
the tetrahydroquinoline moiety extending out of the binding
pocket toward the interface of transmembrane helices TM-A
and TM-D (Figure 5B). A water-mediated hydrogen bond is
established between D231 and the thienopyridine acceptor N,
and a stacking interaction is established with F223. In addition,
the dimethyl group fits neatly into a hydrophobic pocket
formed by residues I194, F195, and L198. Interestingly, and in
direct contrast to compound 1, a G37A mutation in the L.
donovani enzyme (equivalent to G36C in T. cruzi) results in
hypersensitivity to compound 2. Based on our current model,
this can be rationalized by the mutated alanine causing a
general increase in the overall hydrophobicity of the binding
pocket that accommodates the dimethyl group of compound 2.
Mutations in L. donovani cytochrome b directly associated with
resistance to compound 2 include G31A, S207P, and F227I.
G31 is in close proximity to the conserved water molecule that
bridges D231 with the ligand. Bulkier residues in this position
would disrupt this interaction notably affecting the binding of
the compounds. S207 is located within loop 2 at the back of
the hydrophobic pocket where the planar moiety of compound
2 binds. Mutation of S207 to proline is likely to impact the
loop conformation and the shape of the binding pocket. F227
within the hydrophobic pocket defines the conformation of
F223 responsible for forming a stacking interaction with the
ligand. A F227I mutation in L. donovani cytochrome b alters
the conformation of the F223 thus limiting the binding of the
ligand.
In MD simulations, the binding of compounds 1 and 2 to
the Qi site of both L. donovani and T. cruzi cytochrome b
demonstrates a high degree of stability (Figures S6 and S7).
However, simulations with compound 3 illustrate a significant
divergence in behavior between the two parasite enzymes that
may explain the comparatively poor antileishmanial activity of
this compound. In complex with the T. cruzi enzyme,
compound 3 demonstrates notable stability forming numerous
ligand−protein interactions (Figure 5B). In contrast, the
binding of compound 3 to L. donovani cytochrome b is
considerably less stable due to the absence of key interactions
(Figure S8). Of particular note, in the T. cruzi complex, amino
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acid M21 stabilizes the acetanilide moiety of compound 3
through van der Waals interactions. These contacts are not
maintained with the L. donovani enzyme where M21
corresponds to T22. In binding to T. cruzi cytochrome b,
the substituted cyclohexyl ring of compound 3 extends out of
the binding cavity in close proximity to residue G36,
establishing further hydrophobic contacts with residues F33,
L37, and L197. These interactions play a key role in resistance
to compound 3 in T. cruzi with mutations G36C, L197I, and
L197F identified in resistant clones. Mutation of G36 or L197
to bulky residues, such as C or I, will induce a steric clash with
the isopropyl group of compound 3 that accounts for the
reduced potency observed against clonal lines bearing these
mutations.
Assessing the Druggability of the L. donovani and T.
cruzi Qi Site. In an attempt to explain the apparent
promiscuity of the Qi site as a drug target in L. donovani and
T. cruzi, the binding site recognition software SiteMap was
used to assess “druggability” of the pocket.20 In both parasites,
the Qi site is predominantly hydrophobic in nature and is of
considerable size (volume = 394 Å3) (Figure 5C). The
SiteMap analysis characterizes the Qi site as highly druggable.
The computed value of the SiteScore and Druggability Score
for the Qi site was 1.1, well above the cutoff value of 0.8 that is
used to discriminate between drug-binding and non-drug-
binding cavities. Calculation of the exposure and enclosure of
putative binding sites can provide an estimate of how open any
given pocket is to solvent. Highly druggable sites tend to
display low values of exposure (<0.49) and high values of
enclosure (>0.78). The calculated exposure and enclosure
scores for the Qi site of L. donovani and T. cruzi were 0.35 and
0.87, respectively, and confirm the highly druggable properties
of the pocket. In conclusion, the SiteMap calculations showed
that the Qi site of cytochrome b from T. cruzi and L. donovani
displays a combination of features that are optimal for ligand
binding: a large pocket volume, an extended hydrophobic
pocket, high druggability scores, a low cavity exposure, and a
high cavity enclosure. This combination of physicochemical
features confirms the highly druggable nature of this pocket
and may go some way to explaining the significant numbers of
Qi inhibitors identified in our phenotypic screens.
Strategy to Identify Cytochrome b Inhibitors at an
Early Stage of the Drug Discovery Pipeline. Our studies
indicate that a diverse range of chemotypes are capable of
targeting the Qi site of cytochrome b in both L. donovani and
T. cruzi. This structural diversity effectively precludes the use
of structure-based methods to predict cytochrome b inhibitors
at present. In order to prevent our drug discovery portfolios
from becoming enriched with compounds that inhibit this
single molecular target, strategies to rapidly and efficiently
identify cytochrome b inhibitors at an early stage of
development are required. With this mind, resistant clones
bearing a range of representative cytochrome b mutations were
selected to form a cytochrome b-resistant cell line panel. Hits
identified in high-throughput screens (single-point and cidal
potency assays) against T. cruzi intracellular amastigotes were
then screened against our panel of resistant parasites.
Inhibitors specifically targeting the Qi site of cytochrome b
were identified by marked shifts in their potency against panel
cell lines compared to wild-type parasites. To date, 54 primary
screening hits have been assessed in this assay with 11
cytochrome b inhibitors positively identified representing a
remarkable hit rate of almost 20%.
Three representative cytochrome b inhibitors identified via
this screen are shown in Figure 6A and once again illustrate the
structural diversity of compounds capable of targeting the Qi
active site of this enzyme. Indeed, all 11 compounds identified
by this secondary screen are chemically diverse heterocycles
that do not share an obvious pharmacophore and are also
structurally distinct from compounds 1−3. The three
representative compounds chosen for further study elicited a
range of responses from the 5 representative resistant cell lines
in the panel, from hypo- to hypersensitivity (Figure 6A, Figure
S9). All 3 compounds were subsequently confirmed as
inhibitors of complex III activity in T. cruzi epimastigote
lysates (Figure S10). The cytochrome b-resistant panel now
forms a fundamental part of our screening cascade for T.
cruzi21 (Figure 6B) and sits alongside a high-throughput
biochemical assay designed to identify specific inhibitors of
CYP51,22 another promiscuous drug target in T. cruzi. We also
intend to introduce an equivalent cytochrome b resistance
panel into our L. donovani screening cascade.
■ DISCUSSION
The past decade has seen a renewed focus on the discovery of
novel therapeutics for the treatment of kinetoplastid diseases.
In the absence of robustly validated molecular targets to
support target-based studies, large-scale phenotypic screens
have been used to identify start points for drug discovery. This
approach not only allows the efficient identification of parasite
growth inhibitors but also has the potential to identify new and
exploitable molecular targets when coupled to drug target
deconvolution studies. Regrettably, the actual number of new
molecular targets identified via this approach for the
kinetoplastids has been somewhat limited to date.14,23−26
There are likely to be several reasons why primary hits from
phenotypic screens are failing to interact with a diverse range
of molecular targets. However, our current study suggests that
the presence of promiscuous and readily druggable targets
within these parasites may well be masking the identification of
novel targets.
Figure 6. Cytochrome b-resistant cell line panel. (A) Three
representative compounds identified as inhibitors of T. cruzi
cytochrome b as a result of screening against our resistant cell line
panel (also see Figures S3 and S4). (B) Early stages of our adapted in
vitro screening cascade for T. cruzi with addition of the cytochrome b-
resistant cell line panel.
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The Qi site of cytochrome b is certainly not the only highly
druggable target to be identified as a result of the growing
number of high-throughput screens now being carried out
against kinetoplastids. Recent screening initiatives against T.
cruzi have identified a preponderance of sterol 14α-
demethylase (CYP51) inhibitors, thus earmarking this enzyme
as another promiscuous target in T. cruzi.13,27 Indeed, the
proportion of “hits” from our in-house primary phenotypic
screens demonstrating some level of CYP51 inhibition has
been placed as high as 80% (Dr. Manu De Rycker, personal
communication). These findings required steps to be taken to
prevent an enrichment of candidates against this single
molecular target, particularly in light of the recent failure of
posaconazole, an established inhibitor of CYP51, in phase II
clinical trials for CD.11,12 Rapid identification of CYP51
inhibitors is now achieved by triaging primary screening hits in
a high-throughput fluorescence-based CYP51 inhibition
assay22 (Figure 6B). Our studies indicate that similar action
is now required to prevent the overenrichment of VL and CD
drug development pipelines with compounds targeting the Qi
site of cytochrome b. The diversity of chemotypes found to
inhibit the Qi site of cytochrome b has so far prevented the
development of computational solutions to identify the over-
representation of such compounds in our screening libraries. It
is hoped that the cumulative data sets generated by the triaging
assays now in place for both promiscuous targets can be used
to develop predictive algorithms. Undoubtedly, such computa-
tional tools would assist in the design of more diverse
compound libraries.
Micro-organisms are often heavily dependent upon oxidative
phosphorylation for cell maintenance and replication, such that
inhibition of respiratory enzymes, including cytochrome b, can
have dire consequences. Drugs specifically targeting these
enzymes are seen as having significant potential for pathogen
control. With this in mind, the past few years have seen the
development of numerous cytochrome b inhibitors as
antimicrobials.28 Overwhelmingly, these compounds target
the Qo active site of cytochrome b, with the antimalarial
atovaquone perhaps the best known example. Indeed, the Qo
active site of cytochrome b could rightly be considered as
something of a promiscuous drug target in Plasmodium spp and
Mycobacterium tuberculosis.29−32 To our knowledge, there is
currently only one Qi-targeting drug on the market:
cyazofamid is an antifungal agent that is used to treat potato
blight (Phytophthora infestans).33 Thus, it is highly unusual for
the Qi active site of the kinetoplastids to be targeted in this
way.
The range of cytochrome b mutations identified in the
course of this study is noteworthy. As previously discussed, in
kinetoplastids the Cytochrome b gene is encoded by the maxi-
circle DNA of the kinetoplast, equivalent to the mitochondrial
DNA of other eukaryotes. In vertebrates, mutation rates for
mitochondrial-encoded genes have been reported as between 5
and 50 times higher than for genes encoded by nuclear DNA.34
This higher rate has been attributed to DNA damage resulting
from exposure to reactive oxygen species released as
byproducts of oxidative phosphorylation as well as the low
efficiency of DNA repair pathways. The mutation rates for
kinetoplastid-encoded genes have yet to be established but
could be similarly high. Developing inhibitors against a
molecular target with an intrinsically high rate of mutation
clearly has the potential to deliver drugs with a particularly
high resistance potential. However, it should be noted that
malaria parasites bearing mutations in cytochrome b and
resistant to atovaquone are not transmissible by mosquitoes.35
The apparent loss of fitness of atovaquone-resistant parasites in
the mosquito has been associated with the higher respiratory
rate required at this stage of the lifecycle. The failure of these
mutated parasites to be transmitted effectively limits the spread
of atovaquone resistance in the field. It remains to be seen if a
similar fitness cost will be associated with T. cruzi and L.
donovani parasites bearing Qi site mutations. Regardless, future
treatment strategies for VL and CD are likely to focus on the
development of combination therapies that should limit the
propensity for resistance to emerge.
Our current study once again illustrates the vital importance
of MoA studies at an early stage of the drug discovery process.
Such studies have the potential to positively impact drug
discovery in numerous ways. Here, the identification of
multiple compounds targeting cytochrome b enabled the
most promising of these series to be prioritized, while the
development of others was efficiently terminated. Target
identification allowed these series to be ranked primarily on
the basis of selective toxicity versus human cytochrome b. In
conclusion, MoA studies have the potential to guide key
aspects of drug discovery and ultimately play an important role
in the delivery of more effective drugs for NTDs to the clinic.
■ MATERIALS AND METHODS
Test Compounds. Test compounds 1 and 2 were
synthesized by medicinal chemists within the GlaxoSmithKline
and the University of Dundee collaboration funded by the
Wellcome Trust. Compound 3 was developed as part of the
Trypobase Consortium funded under the European Union’s
seventh Framework Programme.36 The details of the chemical
syntheses of all 3 compounds will be provided in subsequent
publications.
Purchased Compounds. Antimycin A was purchased
from Sigma. GNF7686 was purchased from Vitas. On receipt,
the purity of each purchased compound was verified by LCMS
and NMR and confirmed to be >85%.
Cell Lines and Culture Conditions. The clonal
Leishmania donovani cell line LdBOB (derived from
MHOM/SD/62/1S-CL2D) was grown as promastigotes at
28 °C in modified M199 media.37 T. cruzi epimastigotes from
the Silvio strain (MHOM/BR/78/Silvio; clone X10/7A38)
were grown at 28 °C in RTH/FBS [RPMI 1640 medium
supplemented with trypticase (0.4%), 25 μM hemin, 17 mM
Hepes (pH7.4), and 10% (v/v) heat-inactivated fetal bovine
serum (FBS, PAA Laboratories; now GE Healthcare)].39
Bloodstream T. brucei bloodstream form “single marker” S427
(T7RPOL TETR NEO) were cultured in the presence of
G418 (15 μg mL−1) at 37 °C in HMI9-T media in the
presence of 5% CO2.
40 Procyclic form T. brucei 427 strain
containing T7 RNA polymerase and Tet repressor protein,
under control of G418 (15 μg mL−1) and hygromycin (50 μg
mL−1), respectively, were grown at 28 °C without CO2 in
SDM-79 medium41 containing 15% (v/v) heat-inactivated
FBS, 2 g L−1 sodium bicarbonate, 2 mM glutamax
(Invitrogen), and 22.5 μg mL−1 hemin.
Drug Sensitivity Assays (Extracellular Parasites). T.
cruzi Epimastigotes. To examine the effects of test
compounds on growth, mid log epimastigotes were seeded
into 96-well plates at a cell density of 5 × 105 cells mL−1. Cells
were exposed to test compounds over a range of concen-
trations (2-fold serial dilutions). Cells were incubated for 4
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days, after which 5 mM resazurin was added to each well,
before measuring fluorescence (excitation of 528 nm and
emission of 590 nm), after a further 24 h incubation. Data were
processed using GRAFIT (Erithacus software) and fitted to a
2-parameter equation, where the data are corrected for
background fluorescence, to obtain the effective concentration
inhibiting growth by 50% (EC50):
=
+ [ ]( )
y
100
1
m
I
EC50
In this equation, [I] represents inhibitor concentration, and m
is the slope factor. Experiments were repeated at least two
times, and the data are presented as the mean plus standard
deviation.
L. donovani Promastigotes. To examine the effects of test
compounds on growth, triplicate promastigote cultures were
seeded with 5 × 104 parasites mL−1. Parasites were grown in 10
mL cultures in the presence of drug for 72 h, after which 200
μL aliquots of each culture were added to 96-well plates; 500
μM resazurin was added to each well and fluorescence
(excitation of 528 nm and emission of 590 nm) measured
after a further 3 h incubation. Data were processed using
GRAFIT as described above.
T. brucei Bloodstream Form. EC50 values for test
compounds were determined as previously described.40
T. brucei Procyclics. To examine the effects of test
compounds on growth, mid log procyclics were seeded into
96-well plates at a cell density of 5 × 105 cells mL−1. Cells were
exposed to test compounds over a range of concentrations (2-
fold serial dilutions). Following 72 h of incubation in the
presence of drug, 500 μM resazurin was added to each well and
fluorescence measured after a further 2 h incubation.
Drug Sensitivity Assays (Intracellular Parasites). T.
cruzi and L. donovani intracellular amastigote drug sensitivity
assays were conducted as previously described.42,43
Generation of Drug-Resistant Parasites. Compound-
resistant cell lines were generated by subculturing clones of
wild-type L. donovani or T. cruzi in the continuous presence of
test compounds. Starting at sublethal concentrations, drug
concentrations in 3 independent cultures were increased in a
stepwise manner, usually by 2-fold. When parasites were able
to survive and grow in concentrations of drug equivalent to 20
times the established EC50 value, the resulting cell lines were
cloned by limiting dilution in the presence of compound.
Three clones (RES I−III) were selected for further biological
study.
Sequencing. Genomic DNA was isolated from resistant
parasites (∼5 × 108) using a standard alkaline lysis protocol.
Whole genome sequencing was performed using a HiSeq4000
next-generation sequencing platform (Beijing Genomics
Institute, Hong Kong). Sequencing reads were aligned to the
Leishmania donovani BPK282A1 genome (v39, tritrypDB) with
maxi-circle (CP022652.1, NCBI) or Trypanosoma cruzi Silvio
X10-1 genome (v39, tritrypDB) with maxi-circle (FJ203996.1,
NCBI) using Bowtie244 and Samtools45 software. Single
nucleotide polymorphisms (SNPs) and indels were called
using Samtools and Bcftools46 where overall quality score
(QUAL) was >100 when compared with the wild-type starter
clone. Chromosome and gene copy number variation (CNV)
analysis, as well as manual confirmation of putative SNPs, was
performed using Artemis.47 All associated data sets have been
deposited with the European Nucleotide Archive under the
following accession numbers: L. donovani compound 1-
resistant clones (PRJEB32040), T. cruzi compound 1-resistant
clones (PRJEB32041), and L. donovani compound 2-resistant
clones (PRJEB32039). The Cytochrome b genes from T. cruzi-
resistant clones generated with compounds 2 and 3 were
sequenced directly in-house using the following primers: 5′-
GAGAGAGAGTTTCGAGAGGGA- 3′ (forward) and 5′-
TCTAAATTCGCCCAAATTCCTCTTA-3′ (reverse). Cyto-
chrome b sequences required RNA editing within the coding
region prior to translation, as previously described.48
Intramacrophage Drug Sensitivity Assays (Resistant
Cell Lines). Human peripheral blood mononuclear cells
(PBMCs) were isolated from buffy coat supplied by the
Scottish National Blood Transfusion Service (SNBTS) from
anonymized donors under agreement with the SNBTS
Committee for Governance of Blood and Tissue Samples for
Nontherapeutic Use. Human PBMCs were isolated from 2
donors/assay using Leucosep tubes filled with Ficoll-Paque
plus, according to the manufacturer’s instructions (Greiner
Bio-One). CD14+ monocytes were subsequently purified using
CD14 microbeads (Miltenyi Biotec) and differentiated for 7
days using human M-CSF (Bio-Techne), as previously
described.23 Macrophages were then incubated with metacyclic
promastigotes (either wild-type or resistant cell lines) at a
multiplicity of infection of 5 for 16−24 h at 37 °C 5% CO2.
Extracellular parasites were removed by washing three times
with fresh culture media. Adherent PBMCs were detached
from Petri dishes using a cell scraper following incubation with
Versene, plated at 5 × 104 cells per well into 96-well plates
prestamped with 500 nL test compounds, and incubated at 37
°C in 5% CO2 for 96 h. Plates were processed as previously
described.23 Images were analyzed using Columbus image
analysis software (PerkinElmer) and compound potencies
calculated in XLFit. The data were fitted to the following
sigmoidal model:
= +
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Here, y = total number of amastigotes per well, D = minimum
value of y, R = range of y, x = drug concentration, E = EC50,
and n = slope factor.
Complex III Assay. Measurement of complex III activity
was performed as described in Khare et al., 2015,14 with minor
changes. Briefly, L. donovani promastigotes and T. cruzi
epimastigotes were harvested by centrifugation (1600g, 10
min, RT) and washed in Buffer A [(10 mM Tris-HCl, pH 7.4,
0.23 M mannitol, 0.07 M sucrose, 0.2 mM EDTA, 0.2% BSA,
0.5 nM phenylmethanesulfonyl fluoride (PMSF)]. The pellet
was resuspended at 10 mg protein mL−1 (equivalent to ∼1 ×
109 cells mL−1) in Buffer A containing 0.1 mg digitonin mg−1
protein and incubated at 26 °C, for 10 min. Lysates were
centrifuged (13 000g, 5 min, RT); the resulting pellets were
washed and finally resuspended in Reaction Buffer (25 mM
potassium phosphate, 5 mM MgCl2, 2.5 mg mL
−1 BSA, pH
7.2). Pellet suspensions (3.6 μL, equivalent to 36 μg) were
added to 491.4 μL of Reaction Buffer plus 1 mM KCN, 0.6
mM maltoside, and 0.1 mM yeast cytochrome c and incubated
with a specific concentration of test compound for 8 min.
Following incubation, absorbance at 550 nm was monitored
for a further 2 min (UV-2401 PC, Shimadzu). Reactions were
initiated by the addition of decylubiquinol (80 μM final
concentration), and the change in absorbance at 550 nM was
monitored for 2 min. For IC50 determinations, the
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decylubiquinol-dependent rate of cytochrome c reduction was
calculated by subtracting the rate achieved prior to
decylubiquinol addition. DMSO (0.2%) was used as a negative
control. IC50 values were obtained using the 2-parameter fit
(GraFit 7, Erithacus software).
Measurement of T. cruzi Epimastigote Respiration.
Compounds were predispensed (150 nL well−1) into 384-well
assay plates using an Echo liquid handler (Labcyte Inc.). For
potency determinations, 11-point dilution curves were
generated with a top concentration of 25 μM. The negative
control for this assay was 0.2% DMSO, equivalent to the final
concentration of solvent used in drug dilutions. The positive
control in this assay was antimycin A at 25 μM.
Our O2 consumption assay was an adaptation of the assay
described by Khare and colleagues.14 Briefly, assay buffer (250
mM sucrose, 15 mM KCl, 5 mM MgCl2, 1 mM EGTA, 30 mM
K2HPO4, pH 7.4; 25 μL) was added to 384-well assay plates
and incubated at 37 °C for 10 min. Mid log T. cruzi
epimastigotes were harvested (1600g for 10 min at 4 °C),
washed three times with buffer A (10 mM Tris-HCl, pH 7.4,
230 mM mannitol, 70 mM sucrose, 0.2 mM EDTA, 0.2%
bovine serum albumin, 0.5 mM PMSF), and finally
resuspended at 1.5 × 108 epimastigotes mL−1. Following
resuspension, 3 × 106 epimastigotes (20 μL) were dispensed
into each well followed by MitoXpress-Xtra probe (15 μL,
Agilent) resulting in a final assay volume of 60 μL. Plates were
gently shaken, and 30 μL of HS mineral oil (Agilent) was then
added to each well to prevent oxygen exchange between the
assay buffer and air. Plates were incubated for 90 min at 37 °C,
and fluorescence was then measured using an EnVision
MultiMode plate reader (PerkinElmer) using excitation and
emission wavelengths of 380 and 650 nm, respectively.
Data were normalized to percent of biological response by
using positive (i.e., highest response achieved using a chemical
tool compound, RactinomycinA) or negative (i.e., lowest response
achieved in the absence of any testing compound, RDMSO)
controls by using the following equation:
= | − |
| − |
×R R
R R
response (%) 100xDMSO
DMSO actinomycinA
where Rx is the assay response measured in the presence of test
compounds.
Homology Modeling. The homology models of L.
donovani and T. cruzi cytochrome b in complex with
ubiquinone bound to the Qi site were built using Modeler
(Version 9.20).49,50 The X-ray structure of avian cytochrome
bc1 ubiquinone complex was used as a template for both
models (PDB code 1BCC, chain C).19 The Qi sites of L.
donovani and T. cruzi cytochrome exhibit 38% and 45%
sequence identity compared to the template sequence. The
sequence alignments were performed using the T-Coffee
algorithm51 (see sequence alignments shown in Figure 5). The
geometries of the homology models were verified using
PROCHECK.52 The resulting Ramachandran plots indicate a
good model quality with 89% and 87% of the residues in the
most favored regions.
In Silico Docking Studies. Molecular docking was
performed using the homology models of cytochrome b from
L. donovani and T. cruzi built with ubiquinone bound in the Qi
site. Compounds 1−3 were docked into the Qi site of both
structures using GLIDE,53 in the standard precision (SP)
mode. The center of the grid was defined using ubiquinone in
the Qi site as a reference. Crystal structures of cytochrome b
bound to ubiquinone or Qi site inhibitors revealed a conserved
water molecule bridging the ligands with residues on
transmembrane helices TM-A and TM-E (Figure S5). This
water molecule was maintained in the docking calculations and
binding mode studies performed in this work. This approach
was validated by predicting the binding pose of antimycin A, a
well-known inhibitor of cytochrome b binding to the Qi site:
docking of antimycin A to L. donovani and T. cruzi cytochrome
b reproduced the binding poses observed in the crystal
structures from different species (avian and bovine, PDB codes
3H1I and 1PPJ, respectively)19,54 (RMSD = 1.6 and 1.5 Å)
(Figure S6). The resulting complexes of cytochrome b bound
to compounds 1−3 were further refined by means of molecular
dynamics (MD) simulations (see details below).
Molecular Dynamics (MD) Simulations. The stability of
each complex was examined by performing three independent
100 ns molecular dynamics (MD) simulations using
Desmond.55 Periodic boundary conditions were used.
OPLS3e force field56 was used for proteins and ligands, and
the simple point charge (SPC) method water model was
applied.57 The systems were neutralized by adding the
appropriate number of counterions. The cutoff distance for
the nonbonded interactions was 9 Å. The SHAKE algorithm
was applied to all bonds involving hydrogens, and an
integration step of 2.0 fs was used throughout.58 The systems
were simulated at constant temperature (300 K) and pressure
(1 atm) for 100 ns. Cytochrome b is a component of the
cytochrome bc1 complex formed by multiple subunits
embedded in the inner mitochondrial membrane. However,
the simulated systems display a unique cytochrome b subunit.
Hence, to prevent any major conformational changes within
the cytochrome b structure as a result of the absence of the
neighboring subunits, positional restraints (5 kcal mol−1 Å2)
were applied on the backbone atoms of cytochrome b during
simulations.
Qi Site Physicochemical Properties. The site recognition
software SiteMap was used to interrogate the Qi sites of
cytochrome b from L. donovani and T. cruzi in terms of
physicochemical properties (hydrophobic/hydrophilic nature),
volume, exposure, and enclosure.20 Based on those properties,
an overall “SiteScore” and “Druggability” score (Dscore) were
generated providing an estimate value of the druggability of the
pocket. Using the default settings, scores >1.0 indicate a very
promising druggable area while scores of 0.8 define the limit
between drug-binding and non-drug-binding cavities.
Cytochrome b-Resistant Cell Line Panel. T. cruzi X10/7
epimastigotes (wild-type and representative cytochrome b-
resistant lines) were maintained at 28 °C in RTH media. Test
compounds were dispensed using a LabCyte ECHO into
Greiner 384-well assay plates (Greiner 781080), including four
standard control curves (nifurtimox, posaconazole,
DDD0077085459 and DDD0101224824), a 0% effect vehicle
control (DMSO in columns 11 and 23), and a 100% effect
control (50 μM nifurtimox in columns 12 and 24). Cell
suspension (25 μL at a density of 5 × 105 cell mL−1) was
dispensed into each well of the assay plates and left to settle at
room temperature for 40 min, followed by incubation at 28 °C
for 96 h. Parasite growth was assessed with the BacTiter-Glo
luminescence reagent (25 μL well−1) using a PerkinElmer
Victor 3 or BMG Labtech PHERAstar plate reader. All raw
data were normalized to percent inhibition based on the raw
data values for the 0% and 100% effect controls. For potency
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determinations curve fitting was carried out using the following
4-parameter equation:
= + −
+ ( )
y A
B A
1
x
D
10C
with A = minimum y value, B = maximum y value, C = log
EC50, D = slope factor, y = % inhibition, and x = concentration
[M].
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